NCT06265792

Brief Summary

The goal of this clinical trial is to test the efficacy of stellate ganglion block in Obstructive Sleep Apnea. The main question it aims to answer are: • Can stellate ganglion block improve Obstructive Sleep Apnea? Patients were randomly divided into two groups, all provided with routine therapy. Based on this, the experimental group was given stellate ganglion block. The video fluoroscopic swallowing study was done to test the swallowing function before and after the study.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 24, 2024

Completed
27 days until next milestone

First Posted

Study publicly available on registry

February 20, 2024

Completed
10 days until next milestone

Study Start

First participant enrolled

March 1, 2024

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2024

Completed
14 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 15, 2024

Completed
Last Updated

March 6, 2024

Status Verified

March 1, 2024

Enrollment Period

9 months

First QC Date

January 24, 2024

Last Update Submit

March 2, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Epworth Sleepiness Scale

    This scale measures daytime sleepiness. By scoring the level of sleepiness in different situations, it can help evaluate whether a patient has OSA or other sleep disorders.Scores range from 0-24. Higher scores indicate more severe daytime sleepiness.

    day 1 and day 20

Secondary Outcomes (1)

  • Apnea-Hypopnea Index

    day 1 and day 20

Study Arms (2)

The experimental group

EXPERIMENTAL

All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy.The experimental group was given Stellate Ganglion Block.

Behavioral: routine rehabilitation treatmentProcedure: Stellate ganglion block

The control group

ACTIVE COMPARATOR

All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy.

Behavioral: routine rehabilitation treatment

Interventions

All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy

The control groupThe experimental group

The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

The experimental group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients aged over 18 years diagnosed with OSA by polysomnography
  • Patients with moderate to severe OSA (AHI \> 15 events per hour)
  • Patients who have undergone continuous positive airway pressure (CPAP) treatment for at least 3 months but have not achieved satisfactory therapeutic effects
  • Patients who voluntarily agree to receive stellate ganglion block (SGB) treatment and sign the informed consent form

You may not qualify if:

  • Patients with a history of allergy or contraindications to local anesthetics or corticosteroids
  • Patients with severe cardiovascular, cerebrovascular, respiratory, hepatic, or renal diseases
  • Patients with a history of neck surgery or cervical spine disease
  • Patients with psychiatric disorders or other medical conditions that may affect the safety or effectiveness of SGB treatment
  • Pregnant or lactating women
  • Patients who have participated in other clinical trials within the past 3 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Center Rehabilitation Hospital

Seoul, South Korea

Location

MeSH Terms

Conditions

Sleep Apnea, Obstructive

Condition Hierarchy (Ancestors)

Sleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Study Officials

  • Nieto Luis, Doctor

    Site Coordinator of United Medical Group located in Miami

    STUDY CHAIR

Central Study Contacts

Zhefeng Wang, Master

CONTACT

Weiji Zhao, Doctor

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Research Director

Study Record Dates

First Submitted

January 24, 2024

First Posted

February 20, 2024

Study Start

March 1, 2024

Primary Completion

December 1, 2024

Study Completion

December 15, 2024

Last Updated

March 6, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations